Invuity (Invuity) Debt-to-Revenue : 0.83 (As of Jun. 2018)

View and export this data going back to 2015. Start your Free Trial

What is Invuity Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Invuity's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $10.03 Mil. Invuity's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $24.63 Mil. Invuity's annualized Revenue for the quarter that ended in Jun. 2018 was $42.00 Mil. Invuity's annualized Debt-to-Revenue for the quarter that ended in Jun. 2018 was 0.83.

Invuity Debt-to-Revenue Historical Data

The historical data trend for Invuity's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invuity Debt-to-Revenue Chart

Invuity Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Debt-to-Revenue

0.35

0.71

0.69

0.45

0.88

Invuity Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18
Debt-to-Revenue	Get a 7-Day Free Trial														0.59	0.90	0.78	0.88	0.83

Competitive Comparison of Invuity's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, Invuity's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invuity's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Invuity's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Invuity's Debt-to-Revenue falls into.

Invuity Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Invuity's Debt-to-Revenue for the fiscal year that ended in Dec. 2017 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.859	+	29.116)	/	39.619
	=	0.88

Invuity's annualized Debt-to-Revenue for the quarter that ended in Jun. 2018 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(10.026	+	24.632)	/	42.004
	=	0.83

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2018) Revenue data.

Invuity Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Invuity's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Invuity (Invuity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Invuity Inc (NAS:IVTY) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.invuity.com

Invuity Inc is a United States-based commercial-stage medical technology company which utilizes its proprietary Intelligent Photonics technology to develop single-use and reusable illuminated surgical devices. It provides surgeons with illumination and direct visualization of surgical cavities during open minimally invasive and minimal access procedures. Its products include Eikon Illuminated Retractor System, Saber Yankauer, Saber Frazier, Eika Illuminated Retractor System, Breiten Illuminated Retractor System, Eipex Illuminated Retractor System, Eivector Illuminated Retractor System, Waveguide XT System, among others. It sells directly to hospitals, surgeons typically drive the purchasing decision.

Executives

Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Eric W Roberts	director	VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
William W Burke	director	3868 MOCKINGBIRD LN, DALLAS TX 75205
Randall A Lipps	director	1101 EAST MEADOW DR, PALO ALTO CA 94303
Dan Wolterman	director	3721 VALLEY CENTRE DR, SUITE 500, SAN DIEGO CA 92130
James H Mackaness	officer: Chief Financial Officer	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Reza Zadno	director	2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas A Pepper	10 percent owner	C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Philip T Gianos	10 percent owner	2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Keval Desai	10 percent owner	467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022